Exscientia plc

NasdaqGS:EXAI Voorraadrapport

Marktkapitalisatie: US$633.4m

Exscientia Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Exscientia's earnings have been declining at an average annual rate of -44.5%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 4% per year.

Belangrijke informatie

-44.5%

Groei van de winst

-19.3%

Groei van de winst per aandeel

Biotechs Groei van de industrie17.0%
Inkomstengroei-4.0%
Rendement op eigen vermogen-43.8%
Nettomarge-616.5%
Laatste winstupdate30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Recursion's Acquisition Of Exscientia Makes Sense On Some Levels, Not Others

Aug 08

Here's Why We're Watching Exscientia's (NASDAQ:EXAI) Cash Burn Situation

Jul 17
Here's Why We're Watching Exscientia's (NASDAQ:EXAI) Cash Burn Situation

Exscientia: Too Much Pessimism

Jun 10

Exscientia: Drug Discovery Platform Attracting Partners And Cash

May 22

Exscientia: A Strategic Hold In The AI-Driven Drug Discovery Sector (Rating Downgrade)

Feb 26

Is Exscientia (NASDAQ:EXAI) In A Good Position To Invest In Growth?

Jan 11
Is Exscientia (NASDAQ:EXAI) In A Good Position To Invest In Growth?

Earnings Update: Exscientia plc (NASDAQ:EXAI) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Nov 12
Earnings Update: Exscientia plc (NASDAQ:EXAI) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

New Forecasts: Here's What Analysts Think The Future Holds For Exscientia plc (NASDAQ:EXAI)

Aug 31
New Forecasts: Here's What Analysts Think The Future Holds For Exscientia plc (NASDAQ:EXAI)

We're Keeping An Eye On Exscientia's (NASDAQ:EXAI) Cash Burn Rate

Aug 25
We're Keeping An Eye On Exscientia's (NASDAQ:EXAI) Cash Burn Rate

Broker Revenue Forecasts For Exscientia plc (NASDAQ:EXAI) Are Surging Higher

Jul 21
Broker Revenue Forecasts For Exscientia plc (NASDAQ:EXAI) Are Surging Higher

Exscientia (NASDAQ:EXAI) Is In A Good Position To Deliver On Growth Plans

Apr 22
Exscientia (NASDAQ:EXAI) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Exscientia's (NASDAQ:EXAI) Cash Burn Rate

Dec 30
We're Not Very Worried About Exscientia's (NASDAQ:EXAI) Cash Burn Rate

The Exscientia plc (NASDAQ:EXAI) Analysts Have Been Trimming Their Sales Forecasts

Aug 31
The Exscientia plc (NASDAQ:EXAI) Analysts Have Been Trimming Their Sales Forecasts

Exscientia: Using AI To Power Drug Development

Aug 15

Companies Like Exscientia (NASDAQ:EXAI) Can Afford To Invest In Growth

May 29
Companies Like Exscientia (NASDAQ:EXAI) Can Afford To Invest In Growth

Exscientia: Drug Discovery Using AI For Sanofi And Self-Owned Pipeline

Apr 12

Bullish: Analysts Just Made A Sizeable Upgrade To Their Exscientia plc (NASDAQ:EXAI) Forecasts

Jan 09
Bullish: Analysts Just Made A Sizeable Upgrade To Their Exscientia plc (NASDAQ:EXAI) Forecasts

Opbrengsten en kosten

Hoe Exscientia geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

NasdaqGS:EXAI Opbrengsten, kosten en inkomsten (GBP Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 2421-13043111
31 Mar 2420-12938119
31 Dec 2320-14645128
30 Sep 2324-14442135
30 Jun 2322-14841139
31 Mar 2326-14142139
31 Dec 2227-11938129
30 Sep 2225-10035112
30 Jun 2236-693488
31 Mar 2229-592963
31 Dec 2127-492644
30 Sep 2127-362129
30 Jun 2110-391419
31 Mar 2113-24813
31 Dec 2010-22611
31 Dec 199-657

Kwaliteitswinsten: EXAI is currently unprofitable.

Groeiende winstmarge: EXAI is currently unprofitable.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: EXAI is unprofitable, and losses have increased over the past 5 years at a rate of 44.5% per year.

Versnelling van de groei: Unable to compare EXAI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: EXAI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Rendement op eigen vermogen

Hoge ROE: EXAI has a negative Return on Equity (-43.78%), as it is currently unprofitable.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden